Sign Out
Known hypersensitivity to the active substances or to any of the excipients of Stalevo. Severe hepatic impairment. Narrow-angle glaucoma. Pheochromocytoma.
Concomitant use of a nonselective monoamine oxidase (MAO-A and MAO-B) inhibitor (eg, phenelzine, tranylcypromine).
Concomitant use of a selective MAO-A inhibitor and a selective MAO-B inhibitor (see Starting Stalevo Therapy under Dosage & Administration and Other Antiparkinsonian Medicinal Products under Interactions).
A history of neuroleptic malignant syndrome (NMS) and/or nontraumatic rhabdomyolysis.
